Silvercorp acquisition of Adventus hits roadblock
Lawsuit challenging the environmental permit for the target company’s project in Ecuador emerges as bone of contention.
(via TheNewswire)
May 14, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announced today that it has signed an agreement with Kerentech Consulting Ltd. (“Kerentech”), under which Kerentech will support Helix in its ongoing fundraising efforts.
Under the terms of the agreement, Kerentech will assist Helix in closing a bridge financing round of USD 13 million to advance the company’s lead therapeutic programs and strategic priorities through 2025 and beyond. The collaboration reflects Helix’s commitment to accelerating efforts to secure a stable financial platform and fast-track the development of its pipeline candidates this year, beginning with its lead candidate, Tumor Defense Breaker™ L-DOS47.
“We’re pleased to team up with Kerentech as we double down on our efforts to deliver meaningful progress in tackling hard-to-treat cancers as rapidly as possible,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma. “We’re seeing strong engagement from investors and are focused on bringing this round to a timely close —so we can accelerate the clinical development of L-DOS47 in combination with an immune checkpoint inhibitor and push toward better outcomes in non-small cell lung cancer.”
About Kerentech Consulting Ltd.
Kerentech Consulting Ltd. is a global advisory firm specializing in strategic fundraising and corporate development for emerging life sciences and healthcare companies. With deep industry expertise and a robust investor network, Kerentech helps clients unlock capital, accelerate growth, and navigate critical inflection points with confidence. The firm provides tailored support across equity and non-dilutive financing, business strategy, and partnership development, with a focus on delivering long-term value for innovative, mission-driven teams.
About Helix BioPharma Corp.
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/
For more information, please contact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: +1 857 208 7687
Dr. Thomas Mehrling, CEO and Director
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to L-DOS47, LEUMUNA™ and GEMCEDA™. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the assumptions regarding the implied benefits of the transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the risk that the Company's assumptions on which its forward-looking statements are based may not be accurate; the ability of the Company to capitalize on the potential benefits of the transactions; and the risk factors disclosed in the Company's periodic reports publicly filed and available on its SEDAR+ profile at www.sedarplus.ca. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur. There is no assurance that the proposed transactions will be completed in accordance with its terms or at all. The forward-looking statements contained in this news release are made as of the date of this announcement and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
_________________
Copyright (c) 2025 TheNewswire - All rights reserved.
